AM-36

AM-36 is a neuroprotective agent with combined antioxidant and sodium channel blocking actions. AM-36 can inhibit cell apoptosis and ROS prodiction. AM-36 can reduce neuronal damage and DA release after middle cerebral artery occlusion in rats. AM-36 can be used for the researches of inflammation and neurological disease, such as stroke[1][2][3].

Product Specifications

CAS Number

199467-52-2

UNSPSC

12352005

Target

Apoptosis; Reactive Oxygen Species (ROS) ; Sodium Channel

Related Pathways

Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Smiles

ClC1=CC=C(C(CN2CCN(CC2)CC3=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C3)O)C=C1

Molecular Formula

C27H39ClN2O2

Molecular Weight

459.06

References & Citations

[1]Callaway JK, et al. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats. Stroke. 1999 Dec;30 (12) :2704-12; discussion 2712.|[2]Callaway JK, et al. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol. 2001 Apr;132 (8) :1691-8.|[3]Callaway JK, et al. AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion. Neuropharmacology. 2003 May;44 (6) :787-800.